Compare Becton Dickinson and Co (BDX) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Verisign, Inc. — how do they compare? Becton Dickinson and Co trades at $183.48 (market cap $49.41B), while Verisign, Inc. trades at $283.11 (market cap $26.00B). The key difference: Becton Dickinson and Co is the larger of the two by market cap, and Becton Dickinson and Co pays the higher dividend (2.32%). Which is the better fit depends on your goals.
| BDX | VRSN | |
|---|---|---|
Market Cap | $49.41B | $26.00B |
Sector | Health | Technology |
52-Week High | $185.39 | $310.00 |
52-Week Low | $138.62 | $211.49 |
Enterprise Value | $65.51B | $27.31B |
Dividend Yield | 2.32% | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $180.64, up 0.56% today, near its consensus price target of $183. The stock shows bullish technical signals with strong moving averages and recent earnings beats in Q2 2026. Revenue growth is steady, with Q3 2026 reaching $5 billion, though margins face pressure from tariffs. The company maintains a Dividend Aristocrat status with consistent payouts.
Outlook is cautiously optimistic with analyst consensus leaning buy, but risks include margin compression and debt levels. The stock offers stability through dividends and sector resilience, yet investors should monitor earnings sustainability and competitive threats in the medical technology space.
VeriSign (VRSN) trades at $283.56, down 3.33% today, amid mixed quarterly earnings but maintains a bullish technical trend with strong moving averages. The company reported Q2 2026 revenue of $435 million, up 6% year-over-year, with EPS of $2.38 beating estimates. Recent delegation of the .web domain and AI-driven registration growth support a positive outlook, though valuation ratios like P/E of 31.23 suggest a premium.
The stock offers upside to the consensus price target of $320, driven by domain growth and pricing power, but risks include high debt levels and reliance on .com/.net contracts. Analyst sentiment is bullish with 60% buy ratings, yet investors should monitor execution on guidance and contract renewals for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
